Cystic Fibrosis Foundation to invest $500M to support development of therapies for remaining 10% of CF patients

Following the approval of Vertex’s triple therapy last week, the Cystic Fibrosis Foundation is launching a $500 million initiative toward developing therapies for the CF patients whose underlying genetic mutations aren’t amenable to marketed therapies.

CFF SVP of Therapeutics Development Michael Boyle told BioCentury that it may be easy to think there isn’t much unmet need left for CF patients now that there are four approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators that combined treat about 90% of existing patients. ...